Inflammatory Bowel Disease

Top Story

Zinplava may prevent recurrent C. difficile infection in patients with IBD

April 24, 2017

A single infusion of Zinplava was associated with a reduced incidence of recurrent Clostridium difficile infection in patients with inflammatory bowel disease, according to a post hoc analysis of the MODIFY trials presented at the European Congress of Clinical Microbiology and Infectious Diseases.

However, the researchers noted that the results should be interpreted with caution due to the small sample size in the study.

FDA approves biosimilar for infliximab

April 21, 2017
Today, the FDA has approved Merck and Samsung Bioepis’ infliximab biosimilar for injection, which is known as infliximab-abda (Renflexis). It will maintain the…
In the Journals

IBD incidence rapidly increasing in young Canadian children

April 18, 2017
The incidence of inflammatory bowel disease has significantly increased among Canadian children aged younger than 5 years since the turn of the century, according to the…
In the Journals

CDC: Hospitalizations for Crohn's disease remain stable

April 17, 2017
Hospitalizations in the U.S. for an initial diagnosis of Crohn’s disease remained stable between 2003 and 2013, suggesting the increasing rate estimated in the…
CME

Emerging Agents: A Deeper Look

This activity is supported by an educational grant from Receptos.

There are quite a few agents in development for the treatment of ulcerative colitis and Crohn's disease, and many of…
More »
GI Bookshelf

Question 28: I Have A Patient With Biliary-Type Pain, But No Other Evidence Of Bile Duct Disease (Normal Diameter Duct On Ultrasound, Normal Liver Function Tests). How Should Such A Patient Be Managed?

From Curbside Consultation in Endoscopy: 49 Clinical Questions, Second Edition
More »
Featured
International Liver Congress

International Liver Congress

Video
Meeting News

VIDEO: Loftus discusses management of infections in IBD patients

December 13, 2016
More »
Meeting News

Zinplava may prevent recurrent C. difficile infection in patients with IBD

April 24, 2017
A single infusion of Zinplava was associated with a reduced incidence of recurrent Clostridium difficile infection in patients with inflammatory…

FDA approves biosimilar for infliximab

April 21, 2017
Today, the FDA has approved Merck and Samsung Bioepis’ infliximab biosimilar for injection, which is known as infliximab-abda (Renflexis). It…

In the Journals

IBD incidence rapidly increasing in young Canadian children

April 18, 2017
The incidence of inflammatory bowel disease has significantly increased among Canadian children aged younger than 5 years since the turn of the…

In the Journals

CDC: Hospitalizations for Crohn's disease remain stable

April 17, 2017
Hospitalizations in the U.S. for an initial diagnosis of Crohn’s disease remained stable between 2003 and 2013, suggesting the increasing rate…

In the Journals

Ulcerative colitis patients often have different treatment goals than their physicians

April 13, 2017
Patients with ulcerative colitis often had different perceptions of quality of life impact, treatment goals, and attitudes to therapies than their…

Helmsley awards $5 million to study rise of IBD in Asia

April 12, 2017
The Australasian Gastro Intestinal Research Foundation and the Chinese University of Hong Kong received $5.2 million in grants to investigate the…

In the Journals

Patients with IBD may have increased risk for NAFLD

April 10, 2017
Inflammatory bowel disease may contribute to the development of non-alcoholic fatty liver disease, as patients with IBD and NAFLD had longer duration…

Finch, Takeda partner to develop microbiome therapies for IBD

April 7, 2017
Microbiome engineering company Finch Therapeutics announced it has partnered with Takeda to develop a preclinical synthetic microbiome therapeutic…

In the Journals

Asthma may increase IBD risk

April 4, 2017
Researchers associated asthma with subsequent development of Crohn’s disease and early- or late-onset ulcerative colitis in a Canadian…

Miraca adds Simponi to therapeutic drug monitoring platform for IBD

March 31, 2017
Miraca Life Sciences announced it has expanded its InformTx therapeutic drug monitoring platform to include the first assay for Simponi in the U.S…

More Headlines »
Advertisement
Advertisement